TRIAL OF PLATELET-INHIBITING DRUG IN SCLERODERMA - DOUBLE-BLIND-STUDY WITH DIPYRIDAMOLE AND ASPIRIN

被引:57
作者
BECKETT, VL
CONN, DL
FUSTER, V
OSMUNDSON, PJ
STRONG, CG
CHAO, EYS
CHESEBRO, JH
OFALLON, WM
机构
[1] MAYO CLIN & MAYO FDN, DIV RHEUMATOL & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA
[2] MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, ROCHESTER, MN 55905 USA
[3] MAYO CLIN & MAYO FDN, DIV HYPERTENS & INTERNAL MED, ROCHESTER, MN 55905 USA
[4] MAYO CLIN & MAYO FDN, DEPT ORTHOPED, ROCHESTER, MN 55905 USA
[5] MAYO CLIN & MAYO FDN, MED RES STAT SECT, ROCHESTER, MN 55905 USA
来源
ARTHRITIS AND RHEUMATISM | 1984年 / 27卷 / 10期
关键词
D O I
10.1002/art.1780271009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In a randomized, double-blind, controlled study, 28 patients with early scleroderma received dipyridamole (225 mg/day) and aspirin (975 mg/day) or placebo for 1-2 yr. No significant clinical or objective laboratory improvement was noted in either group. Platelet survival time, plasma renin activity and coagulation tests were not predictive of disease course. Biomechanical and vascular tests of the hands correlated with clinical extent of skin induration and presence of finger ulcers, respectively.
引用
收藏
页码:1137 / 1143
页数:7
相关论文
共 28 条